| Project Value | ₹200 CrGreenfield Unit |
|---|---|
| Market Cap | ₹3,345.5 CrMid-range Performer |
| Revenue TTM | ₹505.9 CrSpecialty Chemicals |
| RSI | 68.67Standard Zone |
| Execution period | 21 months |
| Deal value | ₹200 Cr |
| Share of market cap | 6.0% |
| Share of annual revenue | 39.5% |
Key highlights
- Greenfield manufacturing unit to be established at Dahej-III Industrial Estate, Bharuch
- Installation of 344 kilolitres of aggregate reactor capacity for specialty chemicals
- Projected investment of approximately Rs 200 Crore funded via internal accruals and debt
- Implementation timeline estimated at 21 months to meet future market requirements
- Board approved an increase in borrowing limits from Rs 300 Crore to Rs 1,000 Crore
Details of the Dahej Expansion
The company is establishing a new greenfield manufacturing unit at Dahej-III in the Bharuch district of Gujarat. This facility will specifically focus on increasing the manufacturing capacities for various specialty chemicals through the installation of an aggregate reactor capacity of 344 kilolitres. Unlike a simple modification to existing infrastructure, this project represents a completely new manufacturing unit designed to strengthen core infrastructure and address anticipated market requirements.
The total investment of approximately Rs 200 Crore will be financed through a strategic combination of internal accruals and debt instruments, with a target completion window of approximately 21 months from the commencement date.
Strategic Rationale and Financial Flexiblity
- Strategic location at Dahej Industrial Estate provides logistical advantages for chemical exports and raw material procurement
- Project targets the anticipated increase in global demand for niche specialty chemicals and structure directing agents
- Proposed increase in borrowing limits to Rs 1,000 Crore provides a larger financial buffer for capital intensive growth
- Capacity scale-up of 344 KL enables the company to manage larger international orders and improve supply chain reliability
- Re-appointment of founding directors ensures management continuity during the execution of this large-scale infrastructure project
Business Overview and Market Performance
Tatva Chintan is a leading integrated specialty chemical company with a diverse product portfolio including phase transfer catalysts and electrolyte salts for supercapacitor batteries. The company maintains a strong market position with a Durability Score of 70 and a promoter holding of 72.02 percent. For the quarter ended June 30, 2026, the company reported a standalone total income of Rs 150.74 Crore, a notable increase from Rs 110.55 Crore in the corresponding quarter of the previous year.
Standalone net profit for the same period reached Rs 10.45 Crore, reflecting improved operational efficiencies and volume growth across its core chemical segments.
Industry Outlook and Demand Drivers
The specialty chemicals industry in India is benefiting from a structural shift toward domestic manufacturing and increased adoption of green chemistry standards. Tatva Chintan's focus on electrolyte salts positions it to capture growth in the energy storage and electric vehicle segments. The proposed capacity expansion aligns with the industry's projected growth trajectory as global manufacturers seek diversified supply sources.
By scaling up its reactor capacity by 344 KL, the company aims to enhance its responsiveness to large-scale international orders and maintain its competitive edge in the niche pharmaceutical and agrochemical intermediates space while catering to future market demands.
| Share price | ₹1430.2 |
|---|---|
| Market capitalisation | ₹3,345.54 Cr |
| Revenue (annual) | ₹505.86 Cr |
| Net profit (annual) | ₹42.05 Cr |
| Revenue (latest quarter) | ₹134.14 Cr+2.14% vs previous quarter |
| Net profit (latest quarter) | ₹10.32 Cr-31.94% vs previous quarter |
| P/E (TTM) | 79.55×Sector 44.8× |
| Promoter holding | 72.02%0.00% QoQ |
| FII holding | 3.93%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Tatva Chintan Pharma Chem Limited announcing board approval for greenfield capacity expansion and quarterly results. Market figures from a third-party data provider.
